ClinicalTrials.gg
CompletedNCT05515445Updated May 28, 2024

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

A Phase 1 interventional study of Chiglitazar in Hepatic Impairment, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign , able to comply with the requirements of the study.
  • Male or female, between 18 and 79 years of age.
  • 18≤≤30. Weight of male ≥50 kg and Weight of female ≥ 45 kg.
  • No medication within 2 weeks, or stable medication for at least 4 weeks prior to screening.
  • Physical examination, vital signs examination, 12-lead (ECG) examination, and laboratory test have been determined by the investigator to be suitable for participating in this trial.

Exclusion criteria

Exclusion Criteria:

  • Allergic constitution, or allergic to PPAR agonist drugs or any component of Chiglitazar tablets.
  • received PPAR agonist drugs within 2 weeks before screening.
  • Those who have been vaccinated within 4 weeks before screening, or who plan to be vaccinated during the trial.
  • positive test for COVID-19, TP antibody and RPR, or antibody.
  • suffer from uncontrolled serious diseases of cardiovascular, respiratory, gastrointestinal, endocrine, blood, mental/nervous systems within 1 year before screening.
  • have previously undergone surgery that may affect the absorption, distribution, metabolism, and excretion of drugs; anticipate surgery or hospitalization during the trial.
  • Drug abusers, or positive test for drugs of abuse.
  • Smoking more than 5 cigarettes per day on average within 3 months before screening.
  • The average daily alcohol intake in the 3 months prior to screening exceeds the following criteria: more than 14 g for women, or more than 28 g for men; ingested any products containing alcohol within 48 hours before administration; positive alcohol breath test; patients with alcoholic cirrhosis who did not abstinence within 3 months before screening.
  • Ingestion of grapefruit juice/grapefruit juice, food or drink rich in methylxanthine within 48 hours before administration; strenuous exercise or other factors that affect drug absorption, distribution, metabolism, excretion.
  • participated in clinical trials of any drug or medical device within 3 months before screening.
  • donated blood (or blood loss) ≥400 mL within 3 months before screening, or received whole blood or red blood cell suspension.
  • Female subjects who are breastfeeding or positive test of serum pregnancy.
  • \<60 mL/min/1.73m2.
  • Other circumstances assessed by the investigator are not suitable for participating in this trial.

Supplementary exclusion criteria for subjects with hepatic impairment:

  • drug-induced liver injury.
  • acute liver function damage caused by various reasons;
  • complications of liver cirrhosis that the investigator considers inappropriate to participate in the study.
  • diseases that seriously affect bile excretion.

Supplementary exclusion criteria for subjects with normal hepatic function:

  • history of hepatic function damage, or who may have hepatic function damage that the investigator considers to be .
  • positive test for , .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Normal Hepatic Function

    Subjects with normal hepatic function will receive a single 48 mg oral dose of Chiglitazar

    Drug: Chiglitazar

  • Experimental
    Mild Hepatic Impairment

    Subjects with mild hepatic impairment will receive a single 48 mg oral dose of Chiglitazar

    Drug: Chiglitazar

  • Experimental
    Moderate Hepatic Impairment

    Subjects with moderate hepatic impairment will receive a single 48 mg oral dose of Chiglitazar

    Drug: Chiglitazar

  • Experimental
    Severe Hepatic Impairment

    Subjects with severe hepatic impairment will receive a single 48 mg oral dose of Chiglitazar

    Drug: Chiglitazar

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: 4 days

  2. AUC0-t and AUC0-inf

    Area under of the curve (AUC0-t and AUC0-inf)

    Time frame: 4 days

07

Study locations

1 site
  • the First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Aug 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Dec 3, 2022
Primary completionActual
Aug 23, 2023
CompletionActual
Aug 23, 2023
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05515445
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Dec 3, 2022
Primary completion
Aug 23, 2023
Completion
Aug 23, 2023
Last update
May 28, 2024

Study contacts

LiYan Miao
principal investigator · First Affiliated Hospital of Suzhou Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion